natgillin/translations-raw huggingface dataset:
If you take more tablets than you should, or if someone else or a child takes your medicine, contact or go to your nearest emergency centre straight away. 
Če ste vzeli večji odmerek zdravila Incresync, kot bi smeli Če ste vzeli več tablet, kot bi smeli, ali pa je vaše zdravilo vzela druga oseba ali otrok, se nemudoma obrnite na najbližji center za nujno medicinsko pomoč ali se odpravite tja.
Effects of other medicinal products on alogliptin 
Učinki drugih zdravil na alogliptin
This educational pack is aimed at strengthening awareness of important identified risks of bladder cancer and heart failure and the overall recommendations intended to optimise the benefit-risk margin at the patient level. 
To izobraževalno gradivo je namenjeno ozaveščanju o pomembnih ugotovljenih tveganjih za rak sečnega mehurja in srčno popuščanje ter o splošnih priporočilih, da bi dosegli najboljše razmerje med koristjo in tveganjem na ravni bolnika.
Pioglitazone appears to act via activation of specific nuclear receptors (peroxisome proliferator activated receptor gamma) leading to increased insulin sensitivity of liver, fat and skeletal muscle cells in animals. 
Kaže, da pioglitazon deluje preko aktivacije specifičnih jedrnih receptorjev (receptor gama, ki ga aktivira peroksisomski proliferator), kar pri živalih privede do povečane občutljivosti jetrnih, maščobnih in skeletno-mišičnih celic za insulin.
Pack sizes of 10, 14, 28, 30, 56, 60, 90, 98 or 100 film-coated tablets. 
Velikosti pakiranj: 10, 14, 28, 30, 56, 60, 90, 98 ali 100 filmsko obloženih tablet.
Incresync is available in blister packs containing 10, 14, 28, 30, 56, 60, 90, 98 or 100 tablets. 
Zdravilo Incresync je na voljo v pretisnih omotih, ki vsebujejo 10, 14, 28, 30, 56, 60, 90, 98 ali 100 tablet.
Specific pharmacokinetic drug interaction studies have not been performed with Incresync. 
Specifične študije farmakokinetičnih interakcij z zdravilom Incresync niso bile izvedene.
Risk related to alogliptin 
Tveganja, povezana z alogliptinom
Studies in lactating rats indicate that alogliptin is excreted in milk. 
Študije pri podganah med laktacijo kažejo, da se alogliptin izloča v mleko.
Investigations weight increased common alanine aminotransferase increased not known 
Preiskave povečanje telesne mase pogosti zvišanje vrednosti alanin-aminotransferaze neznana
No environmental impact is anticipated from the clinical use of pioglitazone. 
Vpliv na okolje pri klinični uporabi pioglitazona ni pričakovan.
Pioglitazone or placebo was added to existing anti-diabetic and cardiovascular therapy for up to 3.5 years. 
Pioglitazon ali placebo so dodali k že obstoječemu antidiabetičnemu in kardiovaskularnemu zdravljenju, zdravljenje pa je trajalo do 3,5 let.
Immune system disorders hypersensitivity not known hypersensitivity and allergic reactions not known 
Bolezni imunskega sistema preobčutljivost neznana preobčutljivostne in alergijske reakcije neznana
Incresync should not be used in patients with type 1 diabetes mellitus. 
Zdravila Incresync se ne sme uporabljati pri bolnikih s sladkorno boleznijo tipa 1.
This is similar to that seen in a sulphonylurea active comparator group. 
To je podobno kot v primerjalni skupini, ki je prejemala sulfonilsečnino.
If ALT levels are increased to 3 x upper limit of normal during therapy, liver enzyme levels should be reassessed as soon as possible. 
Če se med zdravljenjem vrednosti ALT zvišajo na 3-kratno zgornjo mejo normalnih vrednosti, je treba vrednost jetrnih encimov čim prej znova ovrednotiti.
Alogliptin is a potent and highly selective inhibitor of DPP-4, >10,000-fold more selective for DPP-4 than other related enzymes including DPP-8 and DPP-9. 
Alogliptin je močan in zelo selektiven zaviralec DPP-4, ki je več kot 10.000-krat bolj selektiven za DPP-4 kot za druge sorodne encime, vključno z DPP-8 in DPP-9.
The oedema rates for comparator groups (sulphonylurea, metformin) were 2-5%. 
Delež edemov v skupinah s primerjalnim zdravilom (sulfonilsečnina, metformin) je bil 2-5 %.
Do not take Incresync: - if you are allergic to alogliptin, pioglitazone or any of the other ingredients of this medicine (listed in section 6). 
• če ste alergični na alogliptin, pioglitazon ali katero koli sestavino tega zdravila (navedeno v poglavju 6).
Pioglitazone can cause fluid retention, which may exacerbate or precipitate heart failure. 
Pioglitazon lahko povzroči zastajanje tekočine, kar lahko poslabša ali povzroči srčno popuščanje.
- if you have or have ever had bladder cancer. 
• če imate ali ste kdaj imeli rak sečnega mehurja.
If you have kidney problems your doctor may prescribe you a reduced dose. 
Če imate težave z ledvicami, vam zdravnik lahko predpiše manjši odmerek.
What Incresync is and what it is used for What you need to know before you take Incresync How to take Incresync 
Kaj je zdravilo Incresync in za kaj ga uporabljamo Kaj morate vedeti, preden boste vzeli zdravilo Incresync Kako jemati zdravilo Incresync Možni neželeni učinki
After excluding patients in whom exposure to the medicinal product was less than one year at the time of diagnosis of bladder cancer, there were 7 cases (0.06%) on pioglitazone and 2 cases (0.02%) in control groups. 
Po izključitvi bolnikov, ki so bili v času diagnoze raka sečnega mehurja zdravilu izpostavljeni manj kot eno leto, so ugotovili 7 primerov (0,06 %) raka sečnega mehurja pri pioglitazonu in 2 primera (0,02 %) v kontrolnih skupinah.
Interaction with substrates of CYP 450 isoforms are thus not expected and have not been shown. 
Medsebojno delovanje s substrati za izooblike CYP 450 tako ni pričakovano in tudi ni bilo ugotovljeno.
The observed excess risk of fractures for women in this dataset on pioglitazone is, therefore, 0.8 fractures per 100 patient years of use. 
Opaženo čezmerno tveganje za zlome pri ženskah v tem naboru podatkov za pioglitazon je tako 0,8 zlomov na 100 bolnikov-let uporabe zdravila.
In addition, Incresync can be used to replace separate tablets of alogliptin and pioglitazone in those adult patients aged 18 years and older with type 2 diabetes mellitus already being treated with this combination. 
Poleg tega je zdravilo Incresync mogoče uporabiti za nadomestitev ločenih tablet alogliptina in pioglitazona pri tistih odraslih bolnikih, starih 18 let in starejših, s sladkorno boleznijo tipa 2, ki se že zdravijo s to kombinacijo.
In a pre- and postnatal development study in rats, exposures far above the human exposure at the recommended dose did not harm the developing embryo or affect offspring growth and development. 
V študiji prenatalnega in postnatalnega razvoja pri podganah izpostavljenosti, ki so daleč presegale izpostavljenost človeka pri priporočenem odmerku, niso škodile razvijajočemu se zarodku ali vplivale na rast in razvoj mladičev.
If you are already taking both alogliptin and pioglitazone as single tablets, Incresync can replace them in one tablet. 
Če že jemljete alogliptin in pioglitazon v obliki ločenih tablet, jih zdravilo Incresync lahko nadomesti z eno samo tableto.
If you stop taking Incresync 
Če ste prenehali jemati zdravilo Incresync
See section 2 “Incresync contains lactose”. 
Glejte poglavje 2 “Zdravilo Incresync vsebuje laktozo”.
Patients should be informed of the characteristic symptom of acute pancreatitis: persistent, severe abdominal pain, which may radiate to the back. 
Bolnike je treba seznaniti z značilnim simptomom akutnega pankreatitisa, to je trdovratno in hudo bolečino v trebuhu, ki lahko izžareva v hrbet.
Slight changes in cell counts may show up in blood tests. 
Krvne preiskave lahko pokažejo rahle spremembe števila krvnih celic.
• The risk of bladder cancer and relevant risk minimisation advice. 
• tveganje za nastanek raka sečnega mehurja in ustrezen nasvet za zmanjšanje tveganja.
- if you have a problem with your liver or kidneys. 
• če imate težave z jetri ali ledvicami.
The reports of oedema were generally mild to moderate and usually did not require discontinuation of treatment. 
Edemi so bili v splošnem blagi do zmerni in zaradi njih zdravljenja običajno ni bilo treba prekiniti.
If ALT levels remain > 3 x the upper limit of normal, therapy should be discontinued. 
Če vrednosti ALT ostanejo večje od 3-kratne zgornje meje normalnih vrednosti, je treba zdravljenje prekiniti.
The efficacy and safety of the recommended doses of alogliptin and pioglitazone in a subgroup of patients with type 2 diabetes mellitus and ≥ 65 years old were reviewed and found to be consistent with the profile obtained in patients < 65 years old. 
Učinkovitost in varnost priporočenih odmerkov alogliptina in pioglitazona v podskupini bolnikov s sladkorno boleznijo tipa 2, starih 65 let ali starejših, sta bili ponovno pregledani in ugotovljeno je bilo, da sta konsistentni s profilom, pridobljenim pri bolnikih, mlajših od 65 let.
MARKETING AUTHORISATION NUMBER(S) EU/1/13/842/001-036 
EU/1/13/842/001-036
Concomitant treatment with alogliptin and pioglitazone did not produce new toxicities, nor did it exacerbate any pioglitazone-related findings. 
Sočasno zdravljenje z alogliptinom in s pioglitazonom ni povzročilo novih toksičnih učinkov in ni poslabšalo nobene ugotovitve, povezane s pioglitazonom.
The MAH shall provide an educational pack targeting all physicians who are expected to prescribe/use alogliptin/pioglitazone. 
Imetnik dovoljenja za promet z zdravilom mora zagotoviti izobraževalno gradivo, namenjeno vsem zdravnikom, za katere se pričakuje, da bodo predpisovali/uporabljali alogliptin/pioglitazon.
Interactions with substances metabolised by these enzymes, e.g. oral contraceptives, cyclosporin, calcium channel blockers and HMGCoA reductase inhibitors, are not to be expected. 
Medsebojnih delovanj z zdravili, ki se presnavljajo s temi encimi, npr. s peroralnimi kontraceptivi, ciklosporinom, z zaviralci kalcijevih kanalčkov in zaviralci reduktaze HMGCoA, ni pričakovati.
In clinical studies, patients have taken pioglitazone at higher than the recommended highest dose of 45 mg daily. 
V kliničnih študijah so bolniki prejemali pioglitazon v odmerkih, večjih od največjega priporočenega odmerka 45 mg na dan.
No increase in mortality from heart failure was observed. 
Večje umrljivosti zaradi srčnega popuščanja niso opazili.
Patients (≥ 65 years old) with type 2 diabetes mellitus are considered more susceptible to episodes of hypoglycaemia than patients < 65 years old. 
Bolniki (stari 65 let ali starejši) s sladkorno boleznijo tipa 2 veljajo za bolj dovzetne za epizode hipoglikemije kot bolniki, mlajši od 65 let.
Therapy with Incresync should not be initiated in patients with increased baseline liver enzyme levels (ALT > 2.5 x upper limit of normal) or with any other evidence of liver disease. 
Zdravljenja s pioglitazonom se ne sme uvesti pri bolnikih z izhodiščno zvišano vrednostjo jetrnih encimov (ALT > 2,5-kratna zgornja meja normalnih vrednosti) ali s katerim koli drugimi znakom bolezni jeter.
Although the study failed regarding its primary endpoint, which was a composite of all-cause mortality, non-fatal myocardial infarction, stroke, acute coronary syndrome, major leg amputation, coronary revascularisation and leg revascularisation, the results suggest that there are no long-term cardiovascular concerns regarding use of pioglitazone. 
Čeprav študija ni dosegla primarnega opazovanega dogodka, ki je bil sestavljen iz umrljivosti zaradi vseh vzrokov, neusodnega miokardnega infarkta, možganske kapi, akutnega koronarnega sindroma, velike amputacije na nogah, koronarne revaskularizacije in revaskularizacije na nogah, rezultati kažejo, da glede uporabe pioglitazona ni dolgoročnih kardiovaskularnih zadržkov.
Use with other antihyperglycaemic medicinal products and hypoglycaemia 
Uporaba z drugimi antihiperglikemiki in hipoglikemija
Alogliptin exists predominantly as the (R)-enantiomer (> 99%) and undergoes little or no chiral conversion in vivo to the (S)-enantiomer. 
Večina alogliptina je v obliki (R)-enantiomera (> 99 %) in je in vivo le v manjši meri ali nič podvržen kiralni pretvorbi v (S)-enantiomer.
The relevance to humans of the tumourigenic findings in the male rat cannot be excluded. 
Pomena teh izsledkov o tumorogenosti pri samcih podgan za človeka ni mogoče izključiti.
The adverse reactions are listed by system organ class and frequency. 
Neželeni učinki so navedeni po organskih sistemih in pogostosti.
Incresync is used to lower blood sugar levels in adults with type 2 diabetes. 
Zdravilo Incresync uporabljamo za zniževanje vrednosti krvnega sladkorja pri odraslih s sladkorno boleznijo tipa 2.
The following data are findings from studies performed with alogliptin or pioglitazone individually. 
Naslednji podatki so bili pridobljeni pri študijah, izvedenih posamezno z alogliptinom ali s pioglitazonom.
If you forget to take Incresync 
Če ste pozabili vzeti zdravilo Incresync
Elderly (≥ 65 years old) 
Starostniki (stari 65 let ali starejši)
In vitro data indicate that CYP2D6 and CYP3A4 contribute to the limited metabolism of alogliptin. 
Podatki in vitro kažejo, da CYP2D6 in CYP3A4 prispevata k omejeni presnovi alogliptina.
- if you have cysts on your ovaries (polycystic ovarian syndrome). 
• če imate ciste na jajčnikih (sindrom policističnih jajčnikov).
Higher doses of alogliptin were not teratogenic but resulted in maternal toxicity, and were associated with delayed and/or lack of ossification of bones and decreased foetal body weights. 
Večji odmerki alogliptina niso bili teratogeni, vendar pa so povzročili toksičnost pri materi in so bili povezani z zakasnelo in/ali pomanjkljivo osifikacijo kosti in manjšo telesno maso plodov.
You should also discuss with your doctor if you experience the following side effects: 
Posvetujte se z zdravnikom tudi, če se pojavi kateri od naslednjih neželenih učinkov:
Following initiation of therapy with Incresync, it is recommended that liver enzymes be monitored periodically based on clinical judgement. 
Po uvedbi zdravljenja z zdravilom Incresync je priporočljivo redno spremljanje jetrnih encimov na osnovi klinične presoje.
Combinations not studied 
Neraziskane kombinacije
- if you have a special type of diabetic eye disease called macular oedema (swelling of the back of the eye). 
• če imate posebno obliko diabetične bolezni oči, ki ji pravimo edem rumene pege (oteklina na očesnem ozadju).
Incresync should not be used during pregnancy. 
Zdravila Incresync se med nosečnostjo ne sme uporabljati.
Close monitoring of glycaemic control should be considered (see section 4.4). 
Urejenost glikemije je treba natančno nadzirati (glejte poglavje 4.4).
Pioglitazone effects may be mediated by a reduction of insulin resistance. 
Učinki pioglitazona so morda posledica zmanjšanja odpornosti proti insulinu.
• Patient selection criteria including that Pioglitazone should not be used as first line therapy and emphasising the need for regular review of treatment benefit. 
Vključeno mora biti dejstvo, da se pioglitazona ne sme predpisovati kot zdravila prve izbire in poudarjena potreba po rednem ocenjevanju koristi zdravljenja.
Cardiovascular Safety 
Kardiovaskularna varnost
Patients with rare hereditary problems of galactose intolerance, total lactase deficiency or glucose-galactose malabsorption should not take this medicinal product. 
Bolniki z redko dedno intoleranco za galaktozo, odsotnostjo encima laktaze ali malabsorpcijo glukoze/galaktoze, ne smejo jemati tega zdravila.
No effects on the toxicokinetics of either compound were observed. 
Vplivov katere koli od obeh učinkovin na toksikokinetiko niso opazili.
In the alogliptin group, 11.3% of patients experienced a MACE compared to 11.8% of patients in the placebo group. 
V skupini, ki je prejemala alogliptin, so o MACE poročali pri 11,3 % bolnikov, v skupini, ki je prejemala placebo, pa pri 11,8 % bolnikov.
Following a single intravenous dose of 12.5 mg alogliptin to healthy subjects, the volume of distribution during the terminal phase was 417 L indicating that the active substance is well distributed into tissues. 
Po enkratnem intravenskem odmerku 12,5 mg alogliptina je volumen porazdelitve v končni fazi pri zdravih osebah znašal 417 litrov, kar kaže, da se učinkovina dobro porazdeli v tkiva.
In one-year clinical studies, pioglitazone consistently gave a statistically significant reduction in the albumin/creatinine ratio compared to baseline. 
V enoletnih kliničnih študijah je pioglitazon dosledno statistično značilno znižal razmerje albumin/kreatinin v primerjavi z izhodiščnimi vrednostmi.
Animal studies of up to 13-weeks duration have been conducted with the combined substances in Incresync. 
Pri živalih so bile izvedene študije s kombinacijo učinkovin zdravila Incresync, ki so trajale do 13 tednov.
Symptoms include excessive thirst, frequent urination, loss of appetite, nausea or vomiting and rapid weight loss. 
Simptomi vključujejo pretirano žejo, pogosto uriniranje, izgubo apetita, siljenje na bruhanje ali bruhanje in hitro izgubljanje telesne mase.
In an animal model of familial adenomatous polyposis, treatment with two other thiazolidinediones increased tumour multiplicity in the colon. 
V živalskem modelu družinske adenomatozne polipoze je zdravljenje z dvema drugima tiazolidindionoma povečalo število tumorjev v debelem črevesu.
Furthermore, clinical data do not suggest interaction with p-glycoprotein inhibitors or substrates. 
Klinični podatki tudi ne kažejo na medsebojno delovanje z zaviralci ali s substrati za p-glikoprotein.
Additional symptoms may include general itching and feeling of heat especially affecting the scalp, mouth, throat, palms of hands and soles of feet (Stevens-Johnson syndrome). 
Dodatni simptomi lahko vključujejo splošno srbenje in občutek vročine, še posebej v predelu lasišča, ust, žrela, dlani in podplatov (Stevens-Johnsonov sindrom).
Carnauba wax Glycerol mono-oleate Glycerol mono-oleate 
karnauba vosek karnauba vosek glicerilmonooleat glicerilmonooleat
Total and peak exposure to alogliptin increased proportionately across single doses of 6.25 mg up to 100 mg alogliptin (covering the therapeutic dose range). 
Skupna in največja izpostavljenost alogliptinu sta se v razponu enkratnih odmerkov od 6,25 mg do 100 mg alogliptina (kar pokriva razpon terapevtskih odmerkov) povečevali sorazmerno.
There may be an increased possibility of becoming pregnant because you may ovulate again when you take Incresync. 
V tem primeru obstaja večja možnost zanositve, saj lahko med jemanjem zdravila Incresync ponovno pride do ovulacije.
HOMA analysis shows that pioglitazone improves beta-cell function as well as increasing insulin sensitivity. 
Analiza modela homeostaze (HOMA) kaže, da pioglitazon izboljša delovanje celic beta in poveča občutljivost za insulin.
In these studies, 312 alogliptin/pioglitazone-treated patients were ≥ 65 years old. 
V teh študijah se je z alogliptinom/pioglitazonom zdravilo 312 bolnikov, starih 65 let ali starejših.
- pioglitazone belongs to a group of medicines called thiazolidinediones. 
- Pioglitazon spada v skupino zdravil, imenovano tiazolidindioni.
Therefore, haemodialysis is of little clinical benefit in overdose. 
Hemodializa ima v primeru prevelikega odmerjanja tako le majhno klinično korist.
A clinical study of alogliptin as add-on therapy to pioglitazone demonstrated that there was no clinically relevant increase in hypoglycaemia rate compared to placebo. 
Klinična študija alogliptina kot dodatka k zdravljenju s pioglitazonom je pokazalo, da ne obstaja klinično pomembno povečanje deleža hipoglikemije v primerjavi s placebom.
Mean levels of liver enzymes decreased with treatment with pioglitazone. 
Povprečne vrednosti jetrnih encimov so se pri zdravljenju s pioglitazonom znižale.
- alogliptin belongs to a group of medicines called DPP-4 inhibitors (dipeptidyl peptidase-4 inhibitors). 
- Alogliptin spada v skupino zdravil, imenovano zaviralci DPP-4 (zaviralci dipeptidil-peptidaze-4).
This indicates no time-dependency in the kinetics of alogliptin after multiple dosing. 
To kaže na odsotnost časovne odvisnosti kinetike alogliptina po večkratnem odmerjanju.
Nonfatal Stroke *Overall there were 153 subjects (5.7%) in the alogliptin group and 173 subjects (6.5%) in the placebo group who died (all-cause mortality) 
Neusodna možganska kap * V skupini, ki je prejemala alogliptin, je vsega skupaj umrlo 153 oseb (5,7 %), v skupini, ki je prejemala placebo, pa 173 oseb (6,5 %) (umrljivost zaradi vseh vzrokov).
Interactions with CYP inhibitors are thus not expected and have not been shown. 
Medsebojno delovanje z zaviralci CYP tako ni pričakovano in tudi ni bilo ugotovljeno.
Clinically meaningful reductions in HbA1c compared to control were also observed regardless of baseline background medicinal product dose. 
Klinično pomembna zmanjšanja vrednosti HbA1c v primerjavi s kontrolo so bila opažena tudi ne glede na odmerek osnovno zdravila v izhodišču.
However, the incidences of oedema, weight gain and heart failure were increased. 
Vendar pa je bila pojavnost edemov, povečanja telesne mase in srčnega popuščanja večja.
Incresync is indicated as a second or third line treatment in adult patients aged 18 years and older with type 2 diabetes mellitus: 
Zdravilo Incresync je indicirano kot drugi ali tretji izbor za zdravljenje odraslih bolnikov, starih 18 let in starejših, s sladkorno boleznijo tipa 2:
In case of kidney disease, your doctor may reduce the dose of Incresync. 
V primeru bolezni ledvic bo zdravnik odmerek zdravila Incresync morda zmanjšal.
Following administration of an oral dose of [14C] alogliptin, 76% of total radioactivity was eliminated in the urine and 13% was recovered in the faeces. 
Po uporabi peroralnega odmerka z radioaktivnim izotopom označenega [14C] alogliptina se je 76 % skupne radioaktivnosti izločilo z urinom, 13 % pa z blatom.
The Prescriber Guide should highlight the following: 
Priporočilo za zdravnike mora izpostaviti naslednje:
The highest doses of alogliptin administered in clinical studies were single doses of 800 mg to healthy subjects and doses of 400 mg once daily for 14 days to patients with type 2 diabetes mellitus (equivalent to 32 times and 16 times the recommended daily dose of 25 mg alogliptin, respectively). 
Največji odmerki alogliptina, uporabljeni v okviru kliničnih študij, so bili enkratni odmerki 800 mg pri zdravih osebah in odmerki 400 mg enkrat na dan v obdobju 14 dni pri bolnikih s sladkorno boleznijo tipa 2 (kar je 32-krat oziroma 16-krat več od priporočenega dnevnega odmerka 25 mg alogliptina).
At baseline, patients had a mean age of 61 years, mean duration of diabetes of 9.2 years, and mean HbA1c of 8.0%. 
Povprečna starost bolnikov v izhodišču je bila 61 let, povprečno trajanje sladkorne bolezni 9,2 let, povprečna vrednost HbA1c pa 8,0 %.
Studies in animal models of diabetes showed that concomitant treatment with alogliptin and pioglitazone produced both additive and synergistic improvements in glycaemic control, increased pancreatic insulin content and normalised pancreatic beta-cell distribution. 
Študije na živalskih modelih sladkorne bolezni so pokazale, da je sočasno zdravljenje z alogliptinom in s pioglitazonom povzročilo tako aditivna kot sinergistična izboljšanja urejenosti glikemije, povečalo vsebnost pankreatičnega insulina in normaliziralo porazdelitev pankreatičnih celic beta.
Dietary acidification significantly decreased but did not abolish the incidence of tumours. 
Prehransko zakisanje je pojavnost tumorjev bistveno zmanjšalo, ni pa je odpravilo.
Patients should be advised to promptly seek the attention of their physician if macroscopic haematuria or other symptoms such as dysuria or urinary urgency develop during treatment. 
Bolnikom je treba svetovati, da morajo nemudoma poiskati zdravniško pomoč, če se med zdravljenjem pojavijo makroskopska hematurija ali drugi simptomi, kot sta disurija ali povečana potreba po uriniranju.
Diabetic ketoacidosis 
• Diabetična ketoacidoza.
Your blood sugar will be checked and your dose of Incresync may need to be changed. 
Vrednost krvnega sladkorja bodo preverili in po potrebi spremenili odmerek zdravila Incresync.